ArticleAntimicrobial agents and chemotherapy2024
LiaX is a surrogate marker for cell envelope stress and daptomycin non-susceptibility in
Open access · greenAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Clade-specific evolution and genome plasticity underlying antimicrobial resistance in Enterococcus faecium.Archives of microbiology · 2026Review
- Treatment outcomes of daptomycin- and vancomycin-resistantJAC-antimicrobial resistance · 2026Article
- Non-susceptibility ofMicrobiology spectrum · 2026Article
- Transcriptome analysis suggests the cell wall as the primary target of the antilisterial effect of carrots.Microbiology spectrum · 2026Article
- Antechodynamics and Antechokinetics: Dynamics and Kinetics of Antibiotic Resistance Biomolecules.Biomolecules · 2025Review
- LiaR-dependent gene expression contributes to antimicrobial responses in group AAntimicrobial agents and chemotherapy · 2024Article
Corrections and comments
- Update of
Authors and funding
24 authors at 7 institutions in 2 countries.
Dierdre B Axell-HouseDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Shelby R SimarCenter for Infectious Diseases, University of Texas Health Science Center, School of Public Health, Houston, Texas, USA.
Diana PanessoDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Sandra RinconMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogotá, Colombia.
William R MillerDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-1518-2973
Ayesha KhanDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-0489-0712
Orville A PembertonDepartment of Biosciences, Rice University, Houston, Texas, USA.
Lizbet ValdezDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
April H NguyenMcGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Kara S HoodDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Kirsten RydellDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Andrea M DeTranaltesDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Mary N JonesDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Rachel AtterstromDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Jinnethe ReyesMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogotá, Colombia.ORCID 0000-0002-1722-0734
Pranoti V SahasrabhojaneDepartment of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Geehan SuleymanDepartment of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
Marcus ZervosDepartment of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
Samuel A ShelburneDepartment of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9721-263X
Kavindra V SinghDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0003-3005-3982
Yousif ShamooDepartment of Biosciences, Rice University, Houston, Texas, USA.ORCID 0000-0001-6618-5130
Blake M HansonCenter for Infectious Diseases, University of Texas Health Science Center, School of Public Health, Houston, Texas, USA.ORCID 0000-0003-2949-7818
Truc T TranDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-2696-4196
Cesar A AriasDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0001-9054-9774
Houston Methodist · USThe University of Texas Health Science Center at Houston · USHenry Ford Hospital · USRice University · USThe University of Texas MD Anderson Cancer Center · USUniversidad El Bosque · COVanderbilt University Medical Center · US
Funding
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HAAG, ANTHONY · 2020 to 2025
$12.0MDefining Evolutionary Trajectories: Molecular adaptation to antibiotic resistanceR01AI080714 · NIAID · RICE UNIVERSITY · PI SHAMOO, YOUSIF · 2009 to 2023
$4.3MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MClinical Impact of the Cefazolin Inoculum EffectR01AI173138 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Cesar Augusto Arias · 2023 to 2026
$2.6MMolecular Basis of Infectious Diseases Training GrantT32AI055449 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LORENZ, MICHAEL C · 2005 to 2025
$2.6MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MTexas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3MMobile Genetic Elements and Clinical Outcomes in Staphylococcus aureus BacteremiaK01AI148593 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HANSON, BLAKE M · 2020 to 2023
$519kRole of β-lactamase encoding gene amplification in the development of non-carbapenemase producing, carbapenem-resistant EnterobacteriaceaeR21AI151536 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHELBURNE, SAMUEL A · 2021 to 2022
$470kDefining Evolutionary Trajectories: Molecular adaptation to antibiotic resistanceR56AI080714 · NIAID · RICE UNIVERSITY · PI SHAMOO, YOUSIF · 2013 to 2013
$360kNIAID NIH HHS K01 AI148593NIAID NIH HHS K24 AI121296NIAID NIH HHS L30 AI154520NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI080714NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS R01 AI173138NIAID NIH HHS R21 AI151536NIAID NIH HHS R56 AI080714NIAID NIH HHS T32 AI055449NIAID NIH HHS T32 AI141349
Abstract
Daptomycin (DAP) is often used as a first-line therapy to treat vancomycin-resistant
Indexed as
Cell MembraneDaptomycinEnterococcus faeciumGram-Positive Bacterial InfectionsAnti-Bacterial AgentsBiomarkersDrug Resistance, BacterialEnterococcus faecalisHumansMicrobial Sensitivity TestsPhylogenyReproducibility of ResultsAnti-Bacterial AgentsBiomarkersDaptomycinantibiotic resistancedaptomycinEnterococcus faecium
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.